Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The investigators are doing this research study to learn more about a drug called Xolair
(omalizumab). The investigators want to see if it is an effective treatment for chronic
rhinosinusitis (CRS). Specifically, the investigators want to see whether Xolair will make
nasal polyps smaller and less thick, and relieve symptoms in people with CRS. Polyps are
abnormal growths of tissue that can grow in the lining of your sinuses (the inside of your
nose). The investigators also want to find out if it is safe to use (whether it causes side
effects).